Binghamton University Professor Gary D. James is hoping his new book will take the stress out of researching stress. Offering guidance on topics ranging from the best ways to collect saliva and urine to working with special populations including pregnant women and the elderly, James expects that the book will help students and professionals design more effective field studies and models for stress measurement.
The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.
The lack of health insurance prompts people to forego routine physical exams and have a reduced awareness of cardiovascular risk factors and is associated with increased rates of stroke and death, researchers have concluded.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug.
Researchers at the Gladstone Institute of Cardiovascular Disease announced they have identified a critical genetic factor in the control of many aspects of heart form and function.
An herbal medicinal substance, Crataegus Extract WS?1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
New discoveries offer promise for developing drugs that improve on the therapeutic profile of niacin, the inexpensive, time-tested B-vitamin that boosts levels of HDL cholesterol ? the ?good? cholesterol with the potential to protect people against heart attacks and stroke, scientists reported today.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Some day, heart attack survivors might have a patch of laboratory-grown muscle placed in their heart, to replace areas that died during their attack.
CSL Limited announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL (“good” cholesterol) levels, may reduce the amount of plaque in the coronary arteries of patients with a recent episode of acute coronary syndrome (ACS).